The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

The FDA approved pembrolizumab plus pemetrexted and platinum chemotherapy for advanced or metastatic malignant pleural mesothelioma. The FDA approved frontline pembrolizumab (Keytruda) plus pemetrexed ...

The duo of TAR-200 and cetrelimab was safe and efficacious in the neoadjuvant setting for certain patients with ...

Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.

For patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

Adding relatlimab to nivolumab and chemotherapy improved efficacy but did not increase safety concerns in advanced-stage lung cancer.

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...